Trial *
Publication Motta J, medRxiv, 2020, ,
Dates: 2020-04-01 to 2020-04-25
| Methods | |
| Non-randomized study | |
| Location :
Multicenter / USA Follow-up duration (days): 73 | |
| Inclusion criteria | The study included adult patients admitted with a diagnosis of COVID 19 (ICD-10 code B97.29, J12.89, J18.9, U07.1) between April 1 and April 25, 2020, and treated with AC [anticoagulants] during their inpatient stay. AC was defined as the therapeutic or prophylactic use of enoxaparin or heparin, both regimens started preemptively upon admission. |
| Exclusion criteria | Patients were excluded if they did not take enoxaparin or heparin during their inpatient stay or if they were on other forms of AC prior to or during their hospitalization. Patients who received therapeutic anticoagulation specifically for a thrombotic indication were excluded from this study. |
| Type of analysis | Multivariable logistic regression |
| Interventions | |
| Treatment
therapeutic enoxaparin or heparin (Enoxaparin: 1 or 1.5 mg/kg or titrated higher. Heparin: titrated.) |
|
| Control
prophylactic enoxaparin or heparin (For enoxaparin: 30 or 40 mg. For heparin: 5000 units) | |
| Participants | |
| N analyzed 0 participants (n1=* / n2= *) | |
| Characteristics of participants N=* Mean age : 64.7 220 males Severity : Mild: n=* / Moderate: n=*/ Severe: n=* Critical: n=* | |
| Primary outcome | |
| In the register No | |
| In the report | |
| Documents avalaible |
Protocol NR Statistical plan NR Data-sharing stated NR |
| Risk of bias Overall The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review |
Serious |
| Notes |